^
Association details:
| Biomarker: | REL overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) + Brukinsa (zanubrutinib) (BTK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1529 Biomarker Analysis of Zanubrutinib and Tislelizumab Combination Therapy in Patients with Relapsed/Refractory B-Cell Malignancies
Published date:
11/03/2022
Excerpt:
High mRNA levels of REL were associated with an inferior clinical outcome to zanubrutinib and tislelizumab combination therapy (P < 0.05). Mutations in the tumor suppressor gene TP53 (5/10 [50%] vs 0/7 [0%]) were enriched in non-responders….A high mRNA level of REL or mutations in TP53 may contribute to resistance of zanubrutinib and tislelizumab combination therapy.
DOI:
https://doi.org/10.1182/blood-2022-168474